Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Voyager Therapeutics (VYGR) Accounts Payables (2016 - 2025)

Historic Accounts Payables for Voyager Therapeutics (VYGR) over the last 11 years, with Q3 2025 value amounting to $2.1 million.

  • Voyager Therapeutics' Accounts Payables fell 3303.8% to $2.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.1 million, marking a year-over-year decrease of 3303.8%. This contributed to the annual value of $4.0 million for FY2024, which is 14912.72% up from last year.
  • According to the latest figures from Q3 2025, Voyager Therapeutics' Accounts Payables is $2.1 million, which was down 3303.8% from $1.8 million recorded in Q2 2025.
  • In the past 5 years, Voyager Therapeutics' Accounts Payables ranged from a high of $7.6 million in Q1 2024 and a low of $574000.0 during Q4 2021
  • Moreover, its 5-year median value for Accounts Payables was $2.1 million (2025), whereas its average is $2.4 million.
  • Per our database at Business Quant, Voyager Therapeutics' Accounts Payables crashed by 8251.62% in 2021 and then soared by 34703.83% in 2022.
  • Over the past 5 years, Voyager Therapeutics' Accounts Payables (Quarter) stood at $574000.0 in 2021, then surged by 347.04% to $2.6 million in 2022, then tumbled by 37.49% to $1.6 million in 2023, then skyrocketed by 149.13% to $4.0 million in 2024, then crashed by 47.05% to $2.1 million in 2025.
  • Its Accounts Payables stands at $2.1 million for Q3 2025, versus $1.8 million for Q2 2025 and $2.6 million for Q1 2025.